Stock analysts at UBS Group began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) in a research report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $196.00 price target on the biotechnology company’s stock. UBS Group’s price objective would indicate a potential upside of 45.80% from the stock’s previous close.
Several other analysts also recently issued reports on the stock. Citigroup lifted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. TD Cowen cut their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $192.07.
Check Out Our Latest Research Report on ASND
Ascendis Pharma A/S Trading Down 2.1 %
Hedge Funds Weigh In On Ascendis Pharma A/S
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $60,000. GAMMA Investing LLC increased its position in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the period.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- What is a support level?
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- How Can Investors Benefit From After-Hours Trading
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.